Katrina J. Allen, Nicole A. Mifsud, Robert Williamson, Patrick Bertolino, Winita Hardikar – 23 April 2008 – Liver cell transplantation in humans has been impeded by invariable loss of the graft. It is unclear whether graft loss is due to an immune response against donor hepatocytes. Transplantation with ABO‐matched liver cells was performed in a patient with Crigler‐Najjar type 1. After successful engraftment, there was a gradual loss of graft function.

Akihiko Soyama, Susumu Eguchi, Mitsuhisa Takatsuki, Tatsuki Ichikawa, Masako Moriuchi, Hiroyuki Moriuchi, Tatsufumi Nakamura, Yoshitsugu Tajima, Takashi Kanematsu – 23 April 2008 – This report describes a patient who developed human T‐cell leukemia virus type I–associated myelopathy (HAM) following a living‐donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T‐cell leukemia virus type I (HTLV‐I) carriers.

Stefan G. Hübscher – 23 April 2008

Shirish Huprikar – 23 April 2008

Edie Y. Chan, Les C. Olson, James A. Kisthard, James D. Perkins, Ramasamy Bakthavatsalam, Jeffrey B. Halldorson, Jorge D. Reyes, Anne M. Larson, Adam E. Levy – 23 April 2008 – The use of donation after cardiac death (DCD) donor hepatic allografts is becoming more widespread; however, there have been published reports of increased graft failure from specific complications associated with this type of allograft. The complication of ischemic cholangiopathy (IC) has been reported to occur more frequently after the use of DCD hepatic allografts.

Keli Hansen, Simon Horslen – 23 April 2008 – The aim of this article is to provide essential information for hepatologists, who primarily care for adults, regarding liver‐based inborn errors of metabolism with particular reference to those that may be treatable with liver transplantation and to provide adequate references for more in‐depth study should one of these disease states be encountered. Liver Transpl 14:713–733, 2008. © 2008 AASLD.

Scott Preiss, Margaret Littlejohn, Peter Angus, Alex Thompson, Paul Desmond, Sharon R. Lewin, Joe Sasadeusz, Gail Matthews, Gregory J. Dore, Tim Shaw, Vitini Sozzi, Lilly Yuen, George Lau, Anna Ayres, Chloe Thio, Anchalee Avihingsanon, Kiat Ruxrungtham, Stephen Locarnini, Peter A. Revill – 21 April 2008 – Defective hepatitis B virus DNA (dDNA) is reverse‐transcribed from spliced hepatitis B virus (HBV) pregenomic messenger RNA (pgRNA) and has been identified in patients with chronic HBV (CH‐B).

Clovis Palmer, Taline Hampartzoumian, Andrew Lloyd, Amany Zekry – 21 April 2008 – Adipose tissue releases pro‐inflammatory and anti‐inflammatory mediators, including adiponectin, which elicit a broad range of metabolic and immunological effects. The study aim was to determine in subjects infected with chronic hepatitis C virus (HCV) the effects of total adiponectin and its high‐molecular‐weight (HMW) and low‐molecular‐weight isoforms on HCV‐specific immune responses. Serum levels of total adiponectin and its isoforms were determined by immunoassay.

Melania Manco, Valerio Nobili – 18 April 2008

Hla‐Hla Thein, Qilong Yi, Gregory J. Dore, Murray D. Krahn – 18 April 2008 – Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage‐specific fibrosis progression rates and their determinants in these individuals. A systematic review of published prognostic studies was undertaken.